AbbVie · 1 month ago
2026 Biologics Formulation Development Intern (PhD)
AbbVie is dedicated to discovering and delivering innovative medicines and solutions to tackle serious health issues. The Biologics Formulation Development Intern will support formulation development and characterization experiments, advanced kinetic modeling, and statistical data analyses while gaining valuable experience in the pharmaceutical industry.
BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
Responsibilities
Design and execution of formulation development and characterization experiments
Advanced kinetic modeling and molecular dynamics simulations
Design of Experiments (DoE) and statistical data analyses
Authoring technical reports and scientific presentations
Qualification
Required
Currently enrolled in university, pursuing a PhD in pharmaceutical sciences, chemistry, chemical engineering or other related field
Must be enrolled in university for at least one semester following the internship
Preferred
Expected graduation date between December 2026 – June 2027
Advanced coursework in pharmaceutical, physical chemistry, biophysics, biochemistry, thermodynamics, chemical kinetics, mathematics and/or statistics
Working experience with therapeutic proteins formulation, drug delivery and/or biophysical characterization
Strong communication, teamwork, problem-solving, and time management skills
Benefits
Competitive pay
Relocation support for eligible students
Select wellness benefits and paid holiday / sick time
Company
AbbVie
AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.
H1B Sponsorship
AbbVie has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)
Funding
Current Stage
Public CompanyTotal Funding
$15B2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO
Leadership Team
Recent News
2026-01-23
2026-01-20
2026-01-20
Company data provided by crunchbase